Improvement of sperm motility in patients with asthenozoospermia by kallikrein treatment.
Parenteral and oral application of kallikrein (EC 3.4.21.8)--a kinin-releasing proteinase from porcine pancreatic tissue--significantly stimulates quantitative and qualitative sperm motility in subfertile males with semen criteria of asthenozoospermia. Improvement of sperm motility was found to exist for at least 3 months following termination of the 7 week duration kallikrein treatment. Additionally, a significant increase in the number of spermatozoa was observed 3 and 5 months after starting parenteral application of kallikrein.
D000284:Administration, Oral; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D007267:Injections; D007610:Kallikreins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D013081:Sperm Motility / Q000187:drug effects*; D013268:Stimulation, Chemical
D007610:Kallikreins